-SEC Filing
Summit Therapeutics Closes Deal With Akeso Inc. To In-License Breakthrough Innovative Bispecific Antibody
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that we have completed the closing of our previously announced definitive agreement with Akeso Inc.